Tarlatamab as first-line treatment in combination with carboplatin, etoposide, and PD-L1 inhibitor in patients with extensive-stage small cell lung cancer (ES-SCLC)

Critères de participation
Participants will be included in the study if they meet the following criteria: - Age ≥ 18 years - Participants with histologically or cytologically confirmed ES-SCLC and no prior systemic treatment for ES-SCLC except for the first-line therapy described below. Participants with prior treatment for advanced-stage SCLC are allowed o Parts 1 to 4: The participant must have completed one cycle of platinum-based chemotherapy, etoposide, and PD-L1 inhibitor. Participants who had no access to a PD-L1 inhibitor are allowed o Parts 5 and 6: Participants must have completed 4 cycles of first-line chemotherapy with platinum, etoposide, and PD-L1 inhibitor and must not have experienced disease progression. If there is no access to a PD-L1 inhibitor for first-line treatment, patients who have received 4 to 6 cycles of platinum-based chemotherapy plus etoposide are eligible - Measurable disease according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (only for Parts 1 to 4). - Individuals with treated asymptomatic brain metastases are eligible, provided they meet the following criteria o Only supratentorial and cerebellar metastases allowed o Stereotactic radiosurgery must be completed at least 7 days prior to the first planned dose of study treatment o No need for corticosteroids and no or stable doses of antiepileptics o No signs of radiological progression of the central nervous system (CNS) after definitive therapy at the time of study screening o New or asymptomatic CNS metastases discovered during screening examinations must be irradiated or surgically treated to address CNS metastases. A repeat imaging study is not required if all the above criteria are met. (BASEC)

Critères d'exclusion
Participants will be excluded from the study if any of the following criteria are met: - Untreated or symptomatic brain metastases and/or leptomeningeal disease - History or signs of interstitial lung disease or active non-infectious pneumonitis - Diagnosis of immunodeficiency or receipt of systemic steroid therapy or another form of immunosuppressive therapy within 7 days prior to the first dose of study treatment (BASEC)